PMID- 16644125
OWN - NLM
STAT- MEDLINE
DCOM- 20070116
LR  - 20141120
IS  - 0304-3940 (Print)
IS  - 0304-3940 (Linking)
VI  - 402
IP  - 1-2
DP  - 2006 Jul 10
TI  - Forebrain D1 function and sensorimotor gating in rats: effects of D1 blockade, 
      frontal lesions and dopamine denervation.
PG  - 40-5
AB  - Prefrontal D1 hypoactivity is implicated in the pathophysiology of schizophrenia, 
      and might contribute to sensorimotor gating deficits in schizophrenia patients, 
      based on evidence that D1 blockade in the medial prefrontal cortex (MPFC) reduces 
      prepulse inhibition of startle (PPI) in animal models. PPI is disrupted by 
      systemic and intra-MPFC infusion of the D1 antagonist, SCH23390. We investigated 
      the role of the MPFC in the PPI-disruptive effects of systemic SCH23390 
      administration, and more generally, in the dopaminergic regulation of PPI. PPI 
      was measured in rats after forebrain manipulations, including systemic 
      administration of SCH23390, ibotenic acid lesions of the MPFC, and 6OHDA-induced 
      dopamine (DA) depletion from MPFC or nucleus accumbens. Systemic SCH23390 
      disrupted PPI; these effects were not opposed by ibotenic acid lesions of the 
      MPFC. PPI remained intact after MPFC DA depletion, but--as predicted by Bubser 
      and Koch [M. Bubser, M. Koch, Prepulse inhibition of the acoustic startle 
      response of rats is reduced by 6 hydroxydopamine lesions of the medial prefrontal 
      cortex, Psychopharmacology 113 (1994) 487-492]--a reduction in PPI from pre- to 
      post-surgery correlated significantly with MPFC DA loss. The effects of systemic 
      SCH23390 were not opposed by NAC DA depletion. D1 receptors regulate PPI in rats, 
      but this effect does not appear to be mediated either by the MPFC or by increased 
      mesolimbic DA activity.
FAU - Swerdlow, Neal R
AU  - Swerdlow NR
AD  - Department of Psychiatry, UCSD School of Medicine, La Jolla, CA 92093-0804, 
      United States. nswerdlow@ucsd.edu
FAU - Shoemaker, Jody M
AU  - Shoemaker JM
FAU - Kuczenski, Ronald
AU  - Kuczenski R
FAU - Bongiovanni, Michele J
AU  - Bongiovanni MJ
FAU - Neary, Alaina C
AU  - Neary AC
FAU - Tochen, Laura S
AU  - Tochen LS
FAU - Saint Marie, Richard L
AU  - Saint Marie RL
LA  - eng
GR  - MH01436/MH/NIMH NIH HHS/United States
GR  - MH53484/MH/NIMH NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20060427
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Benzazepines)
RN  - 0 (Dopamine Antagonists)
RN  - 0 (Receptors, Dopamine D1)
RN  - 0 (Sympatholytics)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 333DO1RDJY (Serotonin)
RN  - 8HW4YBZ748 (Oxidopamine)
RN  - VTD58H1Z2X (Dopamine)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - Acoustic Stimulation/methods
MH  - Animals
MH  - Behavior, Animal/drug effects
MH  - Benzazepines/pharmacology
MH  - Chromatography, High Pressure Liquid/methods
MH  - Denervation/methods
MH  - Dopamine/*metabolism
MH  - Dopamine Antagonists/pharmacology
MH  - Lameness, Animal/chemically induced/*physiopathology
MH  - Male
MH  - Norepinephrine/metabolism
MH  - Oxidopamine/pharmacology
MH  - Prefrontal Cortex/drug effects/injuries/*physiology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Dopamine D1/*physiology
MH  - Reflex, Startle/drug effects/physiology
MH  - Serotonin/metabolism
MH  - Sympatholytics/pharmacology
MH  - Time Factors
EDAT- 2006/04/29 09:00
MHDA- 2007/01/17 09:00
CRDT- 2006/04/29 09:00
PHST- 2006/01/14 00:00 [received]
PHST- 2006/03/15 00:00 [revised]
PHST- 2006/03/23 00:00 [accepted]
PHST- 2006/04/29 09:00 [pubmed]
PHST- 2007/01/17 09:00 [medline]
PHST- 2006/04/29 09:00 [entrez]
AID - S0304-3940(06)00326-0 [pii]
AID - 10.1016/j.neulet.2006.03.060 [doi]
PST - ppublish
SO  - Neurosci Lett. 2006 Jul 10;402(1-2):40-5. doi: 10.1016/j.neulet.2006.03.060. Epub 
      2006 Apr 27.